- Home
- ABEO vs CMPX Comparison
ABEO vs CMPX Comparison
Compare ABEO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CMPX
- Stock Information
- Founded
- ABEO 1974
- CMPX 2014
- Country
- ABEO United States
- CMPX United States
- Employees
- ABEO N/A
- CMPX N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- CMPX Health Care
- Exchange
- ABEO Nasdaq
- CMPX Nasdaq
- Market Cap
- ABEO 350.2M
- CMPX 291.8M
- IPO Year
- ABEO 1980
- CMPX N/A
- Fundamental
- Price
- ABEO $6.88
- CMPX $3.35
- Analyst Decision
- ABEO Strong Buy
- CMPX Strong Buy
- Analyst Count
- ABEO 6
- CMPX 8
- Target Price
- ABEO $18.17
- CMPX $13.50
- AVG Volume (30 Days)
- ABEO 687.8K
- CMPX 1.4M
- Earning Date
- ABEO 08-14-2025
- CMPX 08-11-2025
- Dividend Yield
- ABEO N/A
- CMPX N/A
- EPS Growth
- ABEO N/A
- CMPX N/A
- EPS
- ABEO 0.99
- CMPX N/A
- Revenue
- ABEO $400,000.00
- CMPX N/A
- Revenue This Year
- ABEO N/A
- CMPX N/A
- Revenue Next Year
- ABEO $339.63
- CMPX N/A
- P/E Ratio
- ABEO $7.02
- CMPX N/A
- Revenue Growth
- ABEO N/A
- CMPX N/A
- 52 Week Low
- ABEO $3.93
- CMPX $1.27
- 52 Week High
- ABEO $7.54
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- ABEO 56.13
- CMPX 61.47
- Support Level
- ABEO $6.74
- CMPX $3.37
- Resistance Level
- ABEO $7.05
- CMPX $3.52
- Average True Range (ATR)
- ABEO 0.26
- CMPX 0.18
- MACD
- ABEO -0.03
- CMPX 0.04
- Stochastic Oscillator
- ABEO 30.95
- CMPX 76.96
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.